Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Common Equity (2016 - 2025)

Skinvisible's Common Equity history spans 16 years, with the latest figure at -$10.0 million for Q3 2025.

  • For Q3 2025, Common Equity fell 1.39% year-over-year to -$10.0 million; the TTM value through Sep 2025 reached -$10.0 million, down 1.39%, while the annual FY2024 figure was -$9.2 million, 2.22% down from the prior year.
  • Common Equity for Q3 2025 was -$10.0 million at Skinvisible, down from -$9.8 million in the prior quarter.
  • Across five years, Common Equity topped out at -$4.9 million in Q1 2021 and bottomed at -$10.0 million in Q3 2025.
  • The 5-year median for Common Equity is -$8.4 million (2023), against an average of -$7.7 million.
  • The largest annual shift saw Common Equity crashed 44.85% in 2023 before it decreased 1.39% in 2025.
  • A 5-year view of Common Equity shows it stood at -$5.4 million in 2021, then fell by 22.62% to -$6.6 million in 2022, then tumbled by 35.88% to -$9.0 million in 2023, then fell by 2.22% to -$9.2 million in 2024, then dropped by 8.47% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for SKVI's Common Equity are -$10.0 million (Q3 2025), -$9.8 million (Q2 2025), and -$9.5 million (Q1 2025).